Bertrand Coiffier, MD, PhD, on the Phase III LyMa Trial

2014 ASH Annual Meeting

Bertrand Coiffier, MD, PhD, of Centre Hospitalier Lyon-Sud, offers his thoughts on abstract 146, “Rituximab Maintenance vs Wait and Watch After Four Courses of R-DHAP Followed By Autologous Stem Cell Transplantation in Previously Untreated Young Patients With Mantle Cell Lymphoma: First Interim Analysis of the Phase III Prospective LyMa Trial, a Lysa Study,” presented by Steven Le Gouill, MD, PhD.

James O. Armitage, MD, FACP, FRCP, and Richard M. Stone, MD, on Progress Made Against AML and APL

James. O Armitage, MD, FACP, FRCP, of the University of Nebraska Medical Center, and Richard M. Stone, MD, of the Dana-Farber Cancer Institute, discuss advances in treating acute myeloid leukemia and the acute promyelocytic leukema subtype.

Lymphoma

Laurie Sehn, MD

Laurie Sehn, MD, on Nivolumab in Patients With Relapsed/Refractory Hodgkin Lymphoma

Laurie Sehn, MD, of the BC Cancer Agency, on abstract 289, “Nivolumab in Patients With Relapsed or Refractory Hodgkin Lymphoma: Preliminary Safety, Efficacy, and Biomarker Results of a Phase I Study,” presented by Philippe Armand, MD, PhD.

Apr

Today In Oncology

Bertrand Coiffier, MD, PhD, on the Phase III LyMa Trial

Related Videos

Keith McCrae, MD, on Managing Heparin-Induced Thrombocytopenia

Julie M. Vose, MD, MBA, FASCO, on the AETHERA trial

Linda J. Burns, MD, on a Phase II Study of ACE-536 in Beta-Thalassemia

James O. Armitage, MD, FACP, FRCP, and Richard M. Stone, MD, on Progress Made Against AML and APL

Laurie Sehn, MD, on Nivolumab in Patients With Relapsed/Refractory Hodgkin Lymphoma

Metabolic Tumor Volume Predicts CAR T-Cell Therapy Response in LBCL

Can Pesticide Exposure Increase Early-Onset Colorectal Cancer Risk

AI-Powered, Next-Generation Sequencing Blood-Based Assay Evaluated for Detection of Post-HCT Relapse in AML and MDS

MIBC Pembrolizumab With Trimodal Therapy for Bladder Preservation

Long-Term Outcomes With Taletrectinib in ROS1-Positive NSCLC